Atrial thrombi in elective patients considered for atrial fibrillation rhythm control: Risk factors and prognostic value

[1]  J. Sebaaly,et al.  Direct Oral Anticoagulants in Obesity: An Updated Literature Review , 2020, The Annals of pharmacotherapy.

[2]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association , 2020, Circulation.

[3]  A. Camm,et al.  Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[4]  Sang Hoon Lee,et al.  The incidence of left atrial appendage thrombi on transesophageal echocardiography after pretreatment with apixaban for cardioversion in the real-world practice , 2018, PloS one.

[5]  S. Nattel,et al.  Atrial Cardiomyopathy: A Useful Notion in Cardiac Disease Management or a Passing Fad? , 2017, Journal of the American College of Cardiology.

[6]  Corrigendum to: Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry , 2017, European heart journal. Cardiovascular pharmacotherapy.

[7]  Morten Wang Fagerland,et al.  Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry , 2017, European heart journal. Cardiovascular pharmacotherapy.

[8]  D. Grill,et al.  Relationship between body mass index and left atrial appendage thrombus in nonvalvular atrial fibrillation , 2016, Journal of Thrombosis and Thrombolysis.

[9]  M. Aikawa,et al.  Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation. , 2011, Journal of cardiology.

[10]  J. Kalifa,et al.  Body mass index and risk of left atrial thrombus in patients with atrial fibrillation. , 2009, The American journal of cardiology.

[11]  J. Halperin,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.